Development and validation of a real-world model to predict 1-year Level 3 (severe) hypoglycaemia risk in adults with diabetes (the iNPHORM study, United States).

Alexandria A Ratzki-LeewingJason E BlackBridget L RyanGuangyong ZouNeil KlarSusan Webster-BogaertKristina TimcevskaStewart B Harris

Published in: Diabetes, obesity & metabolism (2023)

iNPHORM is the first US-based primary prognostic study on Level 3 hypoglycaemia. Future model implementation could potentiate risk-tailored strategies that reduce real-world event occurrence and overall diabetes burden.

Keyphrases

type diabetes
cardiovascular disease
healthcare
primary care
risk assessment
metabolic syndrome
early onset
risk factors
adipose tissue
smoking cessation
skeletal muscle